283 related articles for article (PubMed ID: 17470784)
1. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
Newbold A; Lindemann RK; Cluse LA; Whitecross KF; Dear AE; Johnstone RW
Mol Cancer Ther; 2008 May; 7(5):1066-79. PubMed ID: 18483296
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Ellis L; Bots M; Lindemann RK; Bolden JE; Newbold A; Cluse LA; Scott CL; Strasser A; Atadja P; Lowe SW; Johnstone RW
Blood; 2009 Jul; 114(2):380-93. PubMed ID: 19383971
[TBL] [Abstract][Full Text] [Related]
4. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.
Whitecross KF; Alsop AE; Cluse LA; Wiegmans A; Banks KM; Coomans C; Peart MJ; Newbold A; Lindemann RK; Johnstone RW
Blood; 2009 Feb; 113(9):1982-91. PubMed ID: 19060243
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.
Inoue S; Riley J; Gant TW; Dyer MJ; Cohen GM
Leukemia; 2007 Aug; 21(8):1773-82. PubMed ID: 17525724
[TBL] [Abstract][Full Text] [Related]
6. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
7. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Thompson RC; Vardinogiannis I; Gilmore TD
PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
[TBL] [Abstract][Full Text] [Related]
9. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
10. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Gillespie S; Borrow J; Zhang XD; Hersey P
Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
12. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
[TBL] [Abstract][Full Text] [Related]
13. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.
Happo L; Cragg MS; Phipson B; Haga JM; Jansen ES; Herold MJ; Dewson G; Michalak EM; Vandenberg CJ; Smyth GK; Strasser A; Cory S; Scott CL
Blood; 2010 Dec; 116(24):5256-67. PubMed ID: 20829369
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
Wiegmans AP; Alsop AE; Bots M; Cluse LA; Williams SP; Banks KM; Ralli R; Scott CL; Frenzel A; Villunger A; Johnstone RW
Cancer Res; 2011 May; 71(10):3603-15. PubMed ID: 21398407
[TBL] [Abstract][Full Text] [Related]
15. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
[TBL] [Abstract][Full Text] [Related]
16. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
17. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.
Jiang X; Tsang YH; Yu Q
Int J Biochem Cell Biol; 2007; 39(5):1016-25. PubMed ID: 17331788
[TBL] [Abstract][Full Text] [Related]
18. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).
Henderson C; Mizzau M; Paroni G; Maestro R; Schneider C; Brancolini C
J Biol Chem; 2003 Apr; 278(14):12579-89. PubMed ID: 12556448
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.
Zhao Y; Tan J; Zhuang L; Jiang X; Liu ET; Yu Q
Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16090-5. PubMed ID: 16243973
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
